Progyny, Inc. (NASDAQ:PGNY) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Progyny, Inc. (NASDAQ:PGNY) have earned an average recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $28.80.

Several analysts recently issued reports on the company. JPMorgan Chase & Co. set a $35.00 price target on Progyny in a report on Wednesday, January 21st. KeyCorp dropped their target price on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday. Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Truist Financial lowered their price target on shares of Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Monday. Finally, Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd.

Insider Activity at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the sale, the executive vice president owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 9.40% of the company’s stock.

Institutional Trading of Progyny

Several large investors have recently added to or reduced their stakes in PGNY. Caitong International Asset Management Co. Ltd acquired a new position in Progyny during the 4th quarter worth $25,000. Cetera Trust Company N.A raised its stake in shares of Progyny by 303.1% during the second quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock valued at $29,000 after purchasing an additional 985 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Progyny by 147.3% in the third quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after purchasing an additional 819 shares during the period. Hantz Financial Services Inc. grew its position in Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after buying an additional 742 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in Progyny by 61.8% in the 3rd quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock valued at $50,000 after buying an additional 894 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Up 1.5%

Shares of NASDAQ:PGNY opened at $17.79 on Thursday. The company has a market cap of $1.46 billion, a PE ratio of 27.37, a P/E/G ratio of 1.19 and a beta of 1.01. Progyny has a fifty-two week low of $16.75 and a fifty-two week high of $28.75. The firm has a 50-day simple moving average of $23.40 and a 200 day simple moving average of $23.00.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The firm had revenue of $318.40 million for the quarter, compared to analysts’ expectations of $314.26 million. During the same quarter last year, the company posted $0.42 earnings per share. Progyny’s revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, research analysts forecast that Progyny will post 0.6 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.